Insight

E. Shyam P. Reddy: Researchers Identified a New Biomarker to Predict Outcomes in KRAS G12C-Mutated NSCLC

E. Shyam P. Reddy/LinkedIn

May 31, 2025, 12:13

E. Shyam P. Reddy: Researchers Identified a New Biomarker to Predict Outcomes in KRAS G12C-Mutated NSCLC

E. Shyam P. Reddy, Professor and Director of the Cancer Biology Program at Morehouse School of Medicine, shared a post on LinkedIn:

“Researchers at the University of Texas MD Anderson Cancer Center in Houston, Texas, have identified a new biomarker called TTF-1 that can help physicians predict the outcome for patients with a specific type of non-small cell lung cancer (NSCLC). Patients with KRAS G12C-mutated NSCLC and high expression of TTF-1 had better chances of survival upon being treated with the KRAS inhibitor sotorasib, while patients with tumors that express low TTF-1 levels responded poorly to the treatment.

‘Since TTF-1 testing is routinely performed in lung cancer diagnosis, it gives physicians an immediate tool to help identify those patients who may benefit from sotorasib and those who may need an alternative or intensified treatment approach,’ explained Ferdinandos Skoulidis, MD, PhD, Associate Professor of Thoracic/Head and Neck Medical Oncology at the MD Anderson Cancer Center and lead author of the study, in a press release. ‘Our findings support the use of biomarkers to personalize care and could guide the precise application of combination strategies with KRAS inhibitors.’

The study, published in the journal Nature Medicine and titled ‘Molecular Determinants of Sotorasib Clinical Efficacy in KRAS G12C-Mutated Non-Small-Cell Lung Cancer,’ analyzed 429 biomarker-evaluable patients with KRAS G12C-mutated NSCLC who had previously been treated with sotorasib in either the Phase II or Phase III clinical trials evaluating sotorasib.

Sotorasib, known under the brand name Lumakras, was approved by the FDA in 2021 for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. As the most common oncogenic driver in non-squamous NSCLC, KRAS is a gene that codes for an important signaling protein in cells. It is mutated in 25-30% of patients with non-squamous NSCLC and its mutation can cause uncontrolled cell proliferation and growth, resulting in tumor development. Sotorasib was developed to inhibit the KRAS G12 mutant protein.

In addition to finding TTF-1 as a predictive biomarker for KRAS G12C-mutated NSCLC patients, the research team also discovered that patients with tumors that are less likely to respond to immunotherapy and lack the expression of the immune checkpoint protein PD-L1, responded better to sotorasib than to chemotherapy.”

Read further.

More posts featuring E. Shyam P. Reddy.

cancer E. Shyam P. Reddy Ferdinandos Skoulidis Lung cancer MD Anderson Cancer Center non small cell lung cancer NSCLC OncoDaily Oncology TTF-1 University of Texas MD Anderson Cancer Center

Oncologist Near Me – Yan Leyfman: A Voice for Innovation, Mentorship, and Impact in Oncology

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals